NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company that entered the public markets through a business combination with Big Rock Partners Acquisition Corp, a blank-check vehicle sponsored by Big Rock Partners. The SPAC completed its initial public offering in 2020, and the de-SPAC merger closed in 2021. NRX operates in the healthcare and life sciences sector, with its pipeline focused on central nervous system disorders and acute critical care conditions, including a lead program targeting bipolar depression. The company filed an 8-K current report with the SEC on August 7, 2026. Sign up at SpacDesk for the full filing record, deal history, and real-time SPAC analytics on NRXP.